BRIEF

on AMOEBA (EPA:ALMIB)

Amoéba obtains approval for its active biocontrol substance in Europe

Stock price chart of AMOEBA (EPA:ALMIB) showing fluctuations.

Amoéba, a greentech company based in Chassieu, France, announces the approval of its biocontrol active substance by the European Commission. This decision marks a key step towards the commercialization of its AXPERA solution in Europe. The five-year approval process confirms the fungicidal efficacy and low risk to the environment and human health of the Willaertia magna Lysate substance.

Following a unanimous vote by all 27 European Union member states, the substance has been granted a low-risk profile. This recognition supports Amoéba's strategy of meeting agricultural needs while reducing the use of synthetic chemicals. The company has already initiated the procedure for marketing authorization in nine European countries.

R. H.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all AMOEBA news